Dyne Therapeutics, Inc (DYN) Stock Price & News

Why is DYN down 4.09%?

Dive Deeper

DYN:NASDAQ

Dyne Therapeutics, Inc

$15.96

-4.09%

(-0.68) 1D

$15.96

0.00% (0.00)

After hours

Closed: Oct 12, 4:00:02 PM GMT-4 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for DYN...

Open

$16.54

High

$16.76

Low

$15.73

Mkt. cap

2.98B

Avg. vol.

3.60M

Volume

2.92M

52-wk high

$27.30

52-wk low

$13.72

EPS

-$3.33

Beta

1.12

Shares outstanding

186.75M

No. of employees

289

Open

$16.54

High

$16.76

Low

$15.73

Mkt. cap

2.98B

Avg. vol.

3.60M

Volume

2.92M

52-wk high

$27.30

52-wk low

$13.72

EPS

-$3.33

Beta

1.12

Shares outstanding

186.75M

No. of employees

289

Related stocks

SMMT

Summit Therapeutics Inc

News stories

From web sources and news partners

BigGo Finance

1 hour ago

S&P 500 Bull Market Turns 4, AI Fuels 118% Surge—Rates Loom as Year 5 Hurdle

Stocktwits

1 hour ago

Big Banks Kick Off Q3 Earnings With S&P 500 Near Records — Strategists Flag What Could Move Markets

BeInCrypto

1 hour ago

Less-Risky Treasuries Now Pay Better Than S&P 500 as Yield Spread Hits -1.5%

BBN Times

4 hours ago

S&P 500 Slips 0.056% to 7,807.20, Holding Just Below Its Record as Chip Stocks Fall and Oil Climbs

About Dyne Therapeutics, Inc

CEO-

Employees289

Founded2017

HeadquartersWaltham, Massachusetts, United States

SectorBiotechnology

Websitedyne-tx.com

Analyst	Recommendation	Action	Price target	Projected	Date
Francois Brisebois LifeSci Capital	Buy	Reiterated	$40.00	+150.6%	09/30/2026
Paul Matteis Stifel Nicolaus	Buy	Reiterated	$37.00	+131.8%	09/30/2026
Andrew Fein H.C. Wainwright	Buy	Reiterated	$32.00	+100.5%	09/30/2026
Ananda Ghosh H.C. Wainwright	Buy	Reiterated	$32.00	+100.5%	09/30/2026
Edward Tenthoff Piper Sandler	Buy	Reiterated	$47.00	+194.5%	09/29/2026
Martin Auster Raymond James	Buy	Maintained	$37.00	+131.8%	09/23/2026
Michael Ulz Morgan Stanley	Buy	Maintained	$36.00	+125.6%	09/09/2026
Luca Issi RBC Capital	Buy	Maintained	$30.00	+88%	09/08/2026
Brian Skorney Robert W. Baird	Buy	Maintained	$26.00	+62.9%	09/09/2026
Andrew Tsai Jefferies	Buy	Maintained	$50.00	+213.3%	09/08/2026
Tessa Romero J.P. Morgan	Sell	Downgraded	$10.00	-37.3%	09/08/2026
Keay Nakae Chardan Capital	Buy	Maintained	$38.00	+138.1%	07/29/2026
Joseph Thome TD Cowen	Buy	Maintained	-	-	07/28/2026
Gavin Clark-Gartner Evercore ISI	Buy	Maintained	$33.00	+106.8%	07/27/2026
Eric Schmidt FCA Cantor Fitzgerald	Buy	Initiated	-	-	07/23/2026
Unknown Analyst J.P. Morgan	Hold	Maintained	-	-	07/20/2026
Unknown Analyst Guggenheim	Buy	Maintained	$50.00	+213.3%	06/30/2026
Andreas Argyrides Chardan Capital	Buy	Reiterated	$40.00	+150.6%	05/21/2026
William Pickering Bernstein	Hold	Reiterated	$24.00	+50.4%	05/13/2026

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	97.22M	95.43M	100.89M	152.17M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	16.67M	20.70M	24.39M	29.49M
Operating expense	113.89M	116.13M	125.28M	181.66M
Total operating expenses	113.89M	116.13M	125.28M	181.66M
Operating income	-113.89M	-116.13M	-125.28M	-181.66M
Other non operating income	-	-	-233.00K	12.00K
EBT including unusual items	-108.04M	-111.96M	-120.85M	-178.56M
EBT excluding unusual items	-108.04M	-111.97M	-120.85M	-178.56M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-108.04M	-111.96M	-120.85M	-178.56M
Net profit margin	-	-	-	-
Earnings per share	-0.76	-0.73	-0.73	-1.08
Interest and investment income	8.48M	7.66M	8.76M	7.79M
Interest expense	-2.90M	-3.19M	-4.20M	-4.60M
Net interest expenses	5.57M	4.46M	4.56M	3.19M
Depreciation and amortization charges	-	-	-	-
EBITDA	-113.37M	-115.61M	-124.73M	-181.10M
Gain or loss from assets sale	-	-	30.00K	-

Ask anything